

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司\*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

### POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 15 JULY 2014

The Board is pleased to announce that the Resolution as set out in the Notice was duly passed by the Independent Shareholders by way of poll voting at the SGM.

Reference is made to the circular (the “**Circular**”) incorporating the notice (the “**Notice**”) of the special general meeting (the “**SGM**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) dated 27 June 2014 regarding the major and connected transaction as contemplated under the Disposal Agreement. Terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

#### POLL RESULTS OF THE SGM

Pursuant to Rule 13.39(5) of the Listing Rules, the Board is pleased to announce that the following ordinary resolution (“**Resolution**”) was duly passed by the Independent Shareholders by way of poll voting at the SGM held on 15 July 2014:

	Resolution	Number of votes (%)	
		For	Against
1.	To approve, among others, the Disposal Agreement and the transactions contemplated thereunder as set out in paragraph (a) of the Resolution in the Notice and the Directors are duly authorized to do all such further acts and things which are in their opinion, necessary, appropriate, desirable or expedient to implement or give effect to the terms, or the transactions contemplated by the Disposal Agreement and the exercise of the conversion rights attaching to the Convertible Bonds as set out in paragraph (b) of the Resolution in the Notice.	222,271,030 (59.92%)	148,670,000 (40.08%)

As at the date of the SGM, the total number of issued Shares in the Company was 2,390,000,000 Shares, in which United Gene, Dr. Mao Yumin, Dr. Xie Yi and their respective associates (including JNJ Investments Limited which was indirectly controlled by Dr. Mao Yumin and Dr. Xie Yi) who were beneficially interested in 534,500,000 Shares, representing approximately 22.36%, were required to abstain from voting on the Resolution at the SGM. As such, the total number of Shares entitling the Independent Shareholders to attend and vote on the Resolution at the SGM was 1,855,500,000 Shares, representing approximately 77.64% of the total issued share capital of the Company as at the date of the SGM. There was no Share in issue entitling the Independent Shareholders to attend and vote only against the Resolution at the SGM.

The Company's Hong Kong branch share registrar and transfer office, Tricor Tengis Limited, was appointed as the scrutineer at the SGM for the vote-taking.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 15 July 2014

*As at the date of this announcement, the Board comprises executive directors as Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and independent non-executive directors as Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

*\* For identification purpose only*